AltPep
Facts
- HQ
- University of Washington
- Sectors
- Biotechnology, Diagnostics, Therapeutics
- Founded
- 2021 Seattle business license
- Type
- Corporation Seattle business license
- Registered name
- AltPep Corporation Seattle business license
- Total raised
- $69.6M SEC Form D filings Total of this company's SEC Form D filings
- Last round
- $44.4M · Jul 2022 SEC Form D
Pictory Wins Startup of the Year at 2024 GeekWire Awards in Seattle Featuring Live Music and Surprise Guests
The 2024 GeekWire Awards in Seattle celebrated Pacific Northwest tech with winners like Pictory, live music, and surprise guests, hosted at Showbox SoDo. The event featured sponsors such as Astound Business Solutions and included networking, entertainment, and a nostalgic tech theme.
University of Washington’s CoMotion Innovation Arm Moving to Condon Hall Near Startup Hall in 2023
The University of Washington's innovation arm, CoMotion, will relocate from the Blume building to Condon Hall near Startup Hall later this year, expanding its space and event capabilities. Startup Hall is part of the Portage Bay Crossing neighborhood, which aims to foster research, education, and entrepreneurship.
AltPep Raises $52.9M to Advance Early Detection and Treatments for Alzheimer’s and Parkinson’s Diseases
AltPep, a University of Washington spinout developing tests and treatments for Alzheimer’s and Parkinson’s, raised $52.9 million in Series B funding to advance clinical trials and regulatory approval for its early detection blood test. The company targets toxic oligomers linked to Alzheimer’s and a related protein in Parkinson’s, aiming to enable early screening and preventive treatment.
Biogen and Eisai's Lecanemab Shows 27% Cognitive Decline Reduction in Major Alzheimer’s Trial, Boosting Seattle’s AltPep
Positive phase 3 trial data of Biogen and Eisai's Alzheimer’s drug lecanemab shows a 27% reduction in cognitive decline and renews hope in amyloid-beta targeting therapies. Seattle startup AltPep sees these results as supportive of its similar approach to detection and treatment.
UW spinout AltPep raises $44.4M as its Alzheimer’s blood test earns FDA breakthrough designation
University of Washington spinout AltPep raised $44.4 million and is developing experimental blood tests to detect Alzheimer’s and Parkinson’s diseases early, plus treatments; its Alzheimer’s test received FDA breakthrough device designation. The three-year-old Seattle startup has 25 employees, raised $23.1M in a 2021 Series A, is hiring, and is pursuing partnerships and clinical-ready development.
AltPep, UW spinout led by Valerie Daggett, raises $23.1M Series A to develop early-detection and therapeutics for Alzheimer’s
Seattle biotech AltPep, spun out of the University of Washington in 2019 and led by founder/CEO Valerie Daggett, raised $23.1 million in a Series A to develop detection tools and preclinical therapies for Alzheimer’s and other amyloid protein diseases. The company’s technology, based on UW-licensed research into alpha-sheet protein structures, will support early detection efforts and expansion into a new 7,500 sq ft Seattle lab.
People
-
Valerie Daggett Executive Officer, Director, Promoter, Founder and CEO
